# Dianthus Therapeutics (DNTH): value investors who own it

1 value investor held Dianthus Therapeutics in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $910k | Added +127% | 2 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sold | 7928 | $796k |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sold | 6771 | $686k |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sold | 3501 | $358k |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sold | 1100 | $114k |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sold | 700 | $73k |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sold | 13309 | $1.4m |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sold | 7215 | $767k |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sold | 2600 | $273k |
| 2026-08-19 | Read Simon | Director | Sold | 2778 | $327k |
| 2026-08-10 | Veness Adam M | SVP, General Counsel and Sec. | Sold | 16167 | $1.8m |
| 2026-08-10 | McGeorge Anne | Director | Sold | 2800 | $303k |
| 2026-08-10 | McGeorge Anne | Director | Sold | 1800 | $197k |
| 2026-08-10 | McGeorge Anne | Director | Sold | 1450 | $156k |
| 2026-08-10 | McGeorge Anne | Director | Sold | 1000 | $111k |
| 2026-08-10 | Read Simon | Director | Sold | 831 | $91k |
| 2026-08-10 | Read Simon | Director | Sold | 737 | $80k |
| 2026-08-10 | McGeorge Anne | Director | Sold | 700 | $78k |
| 2026-08-10 | Read Simon | Director | Sold | 470 | $52k |
| 2026-08-10 | Read Simon | Director | Sold | 397 | $44k |
| 2026-08-10 | Read Simon | Director | Sold | 272 | $30k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/dnth). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.